CTLA4 and neoplasm: We also predicted the response of AML patients to the existing ICIs targeting PD-1 and CTLA-4 using the online TIDE tool, which integrates both intrinsic tumor cell characteristics and the tumor microenvironment to assess the response to immunotherapy.